The small tragedy of the modern drug launch is the brief. It begins as a careful account of a molecule, a disease and a patient. Then it travels. The medical-communications agency adds caveats. The creative shop hunts for a memorable idea. The media team asks for audiences. The access consultants ask whether a payer will reimburse it. By the time everyone reconvenes, the brief has acquired seven owners and nine file names. Nobody has made an obvious mistake. The system has simply edited itself.
Assembled Intelligence exists because Mark Lydiatt and the leaders around Minds + Assembly decided that this routine was not merely irritating. It was the product problem. In October 2025, Minds + Assembly put a new name over a group that already included the medical-communications agency BOLDSCIENCE and healthcare social specialist HashtagHealth. It added Stratevi, a health-economics, outcomes-research and market-access firm, at the same moment. The platform debuted with more than 550 people globally. The transaction price was not disclosed.
That last detail matters. This was not four friends rearranging desks in a loft. Amulet Capital Partners had made a significant growth investment in Minds + Assembly in 2023, then supported a run of acquisitions that also included Awaken Interactive. Assembled Intelligence is the operating thesis produced by that capital: specialist companies can remain sharp while behaving, for the client, like one company.
A holding company with homework
The easy version of an agency platform is a logo slide: put several acquisitions in boxes, draw arrows between them and call the result integrated. Assembled Intelligence makes a more testable claim. Its teams are supposed to share scientific, data-driven, emotional and artificial intelligence. The client should not repeat the brief, disciplines should not compete for budget, and real-world data should sit inside planning rather than arrive as a late appendix.
The menu is unusually broad: medical communications; real-world data; value and access; patient engagement; FDA and regulatory support; omnichannel and digital innovation; social media; media and activation; and creative commercialization. Its customers are pharmaceutical, biotech, medical-device and digital-health companies. The people those customers need to reach are even more varied - physicians, patients, caregivers, payers, regulators and advocacy groups.
“Most platforms connect agencies. We connect intelligence.”Assembled Intelligence's compact argument for the whole enterprise
The difference is easiest to see at the payer. Before Stratevi, the group could explain science, build a brand and find an audience. But a therapy does not reach anyone if its evidence and price fail the access test. Stratevi brought HEOR, pricing and payer strategy into the same room. The acquisition did not add another communication channel. It filled the missing economic argument.
The product hiding inside the service firm
Trelys is where the company becomes more than a collection of expert labor. It is an agentic real-world-data ecosystem that lets teams create cohorts, size markets, trace patient and physician behavior, identify undiagnosed or at-risk patients, and generate triggers for media, field and CRM systems. The interface is designed around plain-language prompts rather than code. Assembled Intelligence says it can turn billions of data points into tailored insight in minutes rather than months.
The telling choice is how Trelys is sold: managed service, where the agency's people produce the insight, or SaaS, where the client's people operate the system. That is a practical answer to two different buyers. One wants an answer. The other wants a capability. It also gives the company a route beyond billing only for hours and projects, though neither software pricing nor revenue is public.
A 2026 company analysis framed the industry's problem with a brutal pair of numbers: 82 percent of pharma respondents thought their healthcare-professional outreach was working; only 28 percent of clinicians agreed. Another study, conducted with inVibe across 150 U.S. clinicians, found the modern contradiction underneath that gap. Doctors use search and AI for speed, but established medical sources remain the trust anchor. The useful marketing job is not to shout into one more channel. It is to make credible evidence easy to find, quick to absorb and simple to verify.
The first thing to fail is the handoff
This is the most copyable piece of the model. A company does not need four acquisitions to use it. Start with one evidence backbone. Give every discipline the same patient, physician and payer definitions. Decide who owns a decision before the meeting, not after it. Put measurement beside strategy early enough to alter the work. Most importantly, make the handoff itself visible. If the audience, claim or objective changes when work crosses a team boundary, record the change.
The idea works best when the problem truly crosses disciplines: a complex launch, a rare-disease patient journey, an uncertain access case, a regulated omnichannel program. It is less convincing for a narrow assignment where a brilliant specialist and a short line of communication are enough. Nor does shared ownership automatically produce shared behavior. Without common incentives, interoperable data, strong privacy controls and somebody empowered to settle disagreements, integration becomes meeting overhead in nicer typography.
A new driver, the same machine
Less than a year after launch, the platform changed CEOs. Andrea Palmer, formerly chief executive of Publicis Health Media, replaced Lydiatt on September 17, 2026. He stayed on the board as a strategic adviser. Palmer arrived with experience integrating AI and programmatic media into a large healthcare organization, and said her focus would be bringing science, creative, media, data analytics and market access together.
The timing makes the appointment more than a personnel note. Assembled Intelligence has already completed the collecting phase. It has specialist brands, private-equity backing, a software proposition, global scale and a No. 27 ranking on the 2026 MM+M Agency 100. Now comes the less photogenic work: turning a set of capabilities into a repeatable client experience.
That is the quiet joke inside the name. Intelligence is easy to assemble on an organization chart. The real achievement would be keeping it assembled when the deadline shortens, the evidence changes, the payer objects and the client asks for one more channel. At that moment, the brief either survives the trip - or resumes collecting file names.